✦ LIBER ✦

Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer

✍ Scribed by Yago Nieto; José Manuel Aramendía; Jaime Espinós; Susana De la Cruz; Oscar Fernández-Hidalgo; Marta Santisteban; Leyre Arbea; Javier Aristu; Rafael Martínez-Monge; Marta Moreno; Luis Pina; Josu Sola; Gerardo Zornoza; Fernando Martínez Regueira

Publisher: Springer
Year: 2009
Tongue: English
Weight: 337 KB
Volume: 65
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-009-1049-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase III trial of adjuvant e

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

✍ Dino Amadori; Rosella Silvestrini; Mario De Lena; Francesco Boccardo; Andrea Roc 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 485 KB

A multicenter randomized phase II study

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

✍ Jean-Yves Pierga; Suzette Delaloge; Marc Espié; Etienne Brain; Brigitte Sigal-Za 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 236 KB